Table 1.

Patient characteristics.

	Type of disease	Conditioning/ GVHD prophylaxis	Stem cell source and characteristics (HLA match)	Donor gender and age	aGVHD	cGVHD organ manifestations at the time of Treg infusion	Discontinued GVHD treatments prior to Treg infusion	GVHD treatment at the time of Treg infusion
Patient 1 male 54 years	B‐CLL	Flu, Bu8/CSA, MTX	BM allo unrelated (10/10)	Male, 39 years	Skin II°	Severe skin III° (progressive, maculopapular rash); oral cavity III° (progressive, ulcerations); eyes II° (stable, keratoconjunctivitis sicca)	Tacro, MMF, Alemtu, Rituxi, Dacli, Evero, ECP, MSC	Prednisolone (10 mg/d)
Patient 2 female 45 yrs	AML	Flu, 8 Gy TBI/CSA mono	PBSC allo related (10/10)	Female, 51 years	No	Severe skin III° (stable, ulcerations, sclerotic features); oral cavity II° (stable)	Tacro, MMF, ECP, MSC	Prednisolone (7.5 mg/d) Everolimus

Alemtu = alemtuzumab (3 × 10 mg subcutaneously per week); AML = acute myeloid leukaemia; B‐CLL = B cell chronic lymphocytic leukaemia; BM = bone marrow; Bu = busulfan, Bu8 (8 mg/kg per os total); CSA = cyclosporin; cyclophosphamide (120 mg/kg total); Dacli = daclizumab (1 mg/kg); ECP = extracorporeal photopheresis; Evero = everolimus; Flu = fludarabine (30 mg/m²/day for 5 days); MTX = methotrexate [graft‐versus‐host disease (GVHD) prophylaxis: cumulative dose 45 mg/m², days 1, 3, 6, 11 after haematopoietic stem cell (HCT); GVHD treatment: 5 mg/m² per week]; MMF = mycophenolate mofetil; MSC = mesenchymal stromal cells [average dose 1 × 10⁶/kg body weight intravenously (i.v.)]; Rituxi = rituximab (100 mg i.v. per week); Tacro = tacrolimus; TBI = hyperfractionated total body irradiation (dose in Gy); HLA = human leucocyte antigen.